- Report
- February 2024
- 200 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- February 2024
- 185 Pages
Global
From €4706EUR$4,900USD£4,052GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1441EUR$1,500USD£1,240GBP
- Report
- November 2021
- 163 Pages
Global
From €3059EUR$3,185USD£2,634GBP
€4370EUR$4,550USD£3,762GBP
- Drug Pipelines
- November 2020
- 65 Pages
Global
From €3362EUR$3,500USD£2,894GBP
- Drug Pipelines
- October 2020
- 58 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Drug Pipelines
- September 2020
- 43 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Drug Pipelines
- June 2020
- 37 Pages
Global
From €3362EUR$3,500USD£2,894GBP
- Report
- May 2018
- 140 Pages
Global
From €3362EUR$3,500USD£2,894GBP
- Report
- November 2022
- 43 Pages
Global
From €3362EUR$3,500USD£2,894GBP
- Report
- October 2022
- 307 Pages
Global
From €2401EUR$2,500USD£2,067GBP
- Report
- August 2022
- 66 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Drug Pipelines
- March 2021
Global
From €1921EUR$2,000USD£1,654GBP
- Drug Pipelines
- July 2020
- 53 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Report
- December 2022
- 94 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Report
- November 2021
- 365 Pages
Global
From €3362EUR$3,500USD£2,894GBP
- Report
- November 2021
- 620 Pages
Global
From €3842EUR$4,000USD£3,308GBP
- Book
- March 2023
- 544 Pages
Virus Like Particles (VLPs) are synthetic particles that mimic the structure of a virus, but lack the genetic material that makes them infectious. VLPs are used in biotechnology for a variety of applications, including vaccine development, drug delivery, and diagnostics. VLPs are produced by expressing viral proteins in a host cell, such as bacteria, yeast, or mammalian cells. This process results in the assembly of the proteins into a particle that closely resembles the native virus.
VLPs are attractive for vaccine development because they can induce a strong immune response without the risk of causing an infection. They can also be used to deliver drugs or other molecules to specific cells or tissues. VLPs are also used in diagnostics, as they can be engineered to bind to specific molecules, allowing them to be used as a detection tool.
Companies in the VLP market include Novavax, Inc., Inovio Pharmaceuticals, Inc., and Vaxart, Inc. Show Less Read more